BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer

Thyroid

Volumn 25, Issue 1, 2015, Pages 71-77

  Falchook, Gerald S ^a   Millward, Michael ^b   Hong, David ^c   Naing, Aung ^c   Piha Paul, Sarina ^c   Waguespack, Steven G ^d   Cabanillas, Maria E ^d   Sherman, Steven I ^d   Ma, Bo ^e   Curtis, Martin ^e   Goodman, Vicki ^e   Kurzrock, Razelle ^f  

^a HealthOne   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF TEXAS   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; DABRAFENIB; DOCETAXEL; GEMCITABINE; INTERLEUKIN 6; OPB 31121; PAZOPANIB; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; TAMOXIFEN; THYROGLOBULIN; TIPIFARNIB; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; VALPROIC ACID; BRAF PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; OXIME;

ADULT; AGED; ALOPECIA; AMYLASE BLOOD LEVEL; ANAPLASTIC THYROID CANCER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; DIFFERENTIATED THYROID CANCER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; GENE MUTATION; HAIR DISEASE; HAIR TEXTURE ABNORMAL; HUMAN; HYPERAMYLASEMIA; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SEBORRHEIC KERATOSIS; SIDE EFFECT; SKIN CARCINOMA; SKIN HYPERTROPHY; SKIN PAPILLOMA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; CARCINOMA, PAPILLARY; GENETICS; MIDDLE AGED; PATHOLOGY; SECONDARY; THYROID NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; OXIMES; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84920841992     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2014.0123     Document Type: Article

References (35)

1. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899.
2. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Penã C, Molnár I, Schlumberger MJ; on behalf of the DECISION investigators. Sorafenib in radioactive iodinerefractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 14:60421-60429.
3. Schlumberger M, Sherman SI 2012 Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 166:5-11.
4. Roberts PJ, Der CJ 2007 Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310.
5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C,Watt S, Hooper S,Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954.
6. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R 2004 Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855-867.
7. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457.
8. Lee JH, Lee ES, Kim YS 2007 Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110:38-46.
9. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM, Clayman GL 2009 High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15:485-491.
10. Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M, Imada T 2007 Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res 27: 3645-3649.
11. Caronia LM, Phay JE, Shah MH 2011 Role of BRAF in thyroid oncogenesis. Clin Cancer Res 17:7511-7517.
12. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/rafmitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93:278-284.
13. Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A 2007 BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 96:1549-1553.
14. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379.
15. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J 2012 The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773.
16. Li C, Lee KC, Schneider EB, Zeiger MA 2012 BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97:4559-4570.
17. Xing M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, Yip L, Mian C, Vianello F, Tuttle RM, Robenshtok E, Fagin JA, Puxeddu E, Fugazzola L, Czarniecka A, Jarzab B, O'Neill CJ, Sywak MS, Lam AK, Riesco-Eizaguirre G, Santisteban P, Nakayama H, Tufano RP, Pai SI, Zeiger MA, Westra WH, Clark DP, Clifton-Bligh R, Sidransky D, Ladenson PW, Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 14:1493-1501.
18. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G 2010 Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab 95:450-455.
19. Laquerre S, Arnone M, Moss K, Yang J, Fisher KE, Kane-Carson LS, Smitheman K 2009 A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation. Mol Cancer Ther 8:B88 (Abstract).
20. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O'Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF 2012 Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893-1901.
21. National Cancer Institute 2011 Common terminology criteria for adverse events (CTCAE), version 3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf (accessed December 2, 2012).
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216.
23. Brookmeyer R, Crowley J 1982 A confidence interval for the mean survival time. Biometrics 38:29-41.
24. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R 2004 B-RAF is a therapeutic target in melanoma. Oncogene 23:6292-6298.
25. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB 2010 Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819.
26. Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI 2013 Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid 23:1277-1283.
27. Liu D, Xing J, Trink B, Xing M 2010 BRAF mutationselective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer 127:2965-2973.
28. Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL 2010 MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther 9:1968-1976.
29. Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE 2012 Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 18:2056-2065.
30. Friday BB, Adjei AA 2008 Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14:342-346.
31. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Dominguez JM, Shen R, Tuttle RM, Larson SM, Fagin JA 2013 Selumetinibenhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 368:623-632.
32. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, MacConaill LE, Hahn WC, Meyerson M, Garraway LA 2011 Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096.
33. Montero-Conde C, Ruiz-Llorente S, Dominguez JM, Knauf JA, Viale A, Sherman EJ, Ryder M, Ghossein RA, Rosen N, Fagin JA 2013 Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 3:520-533.
34. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D 2012 Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095.
35. Chiu AC, Delpassand ES, Sherman SI 1997 Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82:3637-3642.